Literature DB >> 16759765

Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.

Quincy C Moore1, Joseph R Bosarge, Lisa R Quin, Larry S McDaniel.   

Abstract

The effect of priming and boosting with pspA/EF5668 and purified recombinant PspA/EF5668 was examined. With this strategy CBA/N mice were protected against fatal challenge with Streptococcus pneumoniae EF5668. Anti-PspA antibody titers were elevated, and Western analysis with the immune serum demonstrated cross-reactivity with PspA from several different pneumococcal isolates, representing different PspA clades. Immune serum localized cross-reactive epitopes to the alpha-helical domain of PspA/Rx1 and PspA/EF5668. We demonstrated that DNA/protein prime-boost immunizations can enhance protective immunity against pneumococcal challenge.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16759765     DOI： 10.1016/j.vaccine.2006.04.046

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

1.  Immunization with PspA incorporated into a poly(ethylene oxide) matrix elicits protective immunity against Streptococcus pneumoniae.

Authors:  Quincy C Moore; LaShundra Johnson; Michael Repka; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

2.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae Keratitis.

Authors:  Erin W Norcross; Melissa E Sanders; Quincy C Moore; Sidney D Taylor; Nathan A Tullos; Rhonda R Caston; Sherrina N Dixon; Moon H Nahm; Robert L Burton; Hilary Thompson; Larry S McDaniel; Mary E Marquart
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-29       Impact factor: 4.799

Review 4.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

Review 5.  Advances in pneumococcal vaccines: what are the advantages for the elderly?

Authors:  Angel Vila-Córcoles
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production.

Authors:  Daniela M Ferreira; Michelle Darrieux; Maria Leonor S Oliveira; Luciana C C Leite; Eliane N Miyaji
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

7.  Enhancement of the expression of HCV core gene does not enhance core-specific immune response in DNA immunization: advantages of the heterologous DNA prime, protein boost immunization regimen.

Authors:  Ekaterina Alekseeva; Irina Sominskaya; Dace Skrastina; Irina Egorova; Elizaveta Starodubova; Eriks Kushners; Marija Mihailova; Natalia Petrakova; Ruta Bruvere; Tatyana Kozlovskaya; Maria Isaguliants; Paul Pumpens
Journal:  Genet Vaccines Ther       Date:  2009-06-08

8.  Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.

Authors:  Christopher J Greene; Laura R Marks; John C Hu; Ryan Reddinger; Lorrie Mandell; Hazeline Roche-Hakansson; Natalie D King-Lyons; Terry D Connell; Anders P Hakansson
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

9.  Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting.

Authors:  Audrey Tanghe; Jean-Pierre Dangy; Gerd Pluschke; Kris Huygen
Journal:  PLoS Negl Trop Dis       Date:  2008-03-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.